Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers

NCT02198326 ↗

Phase 1 Completed 32 enrolled Boehringer Ingelheim

RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single intranasal administration of increasing doses in healthy male and female volunteers

Timeline

Start: 1999-07
Primary completion: 1999-08
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OLCEGEPANT	Small molecule	—	Intranasal

Indications

No indication recorded.